LA Private

Uncategorized

Stocks of the Hour: Asian Battery Metals PLC, Li-S Energy, LCL Resources

Asian Battery Metals PLC (ABM, ASX:AZ9) has announced results from the remaining assay data of its Phase 1 diamond drilling program at the 100% Oval Copper-Nickel-Platinum prospect in Mongolia’s Gobi-Altai region. The Company’s Managing Director commented, “After 4 years of exploration, it’s exciting to confirm a substantial copper-nickel deposit potential with high-grade zones. Future work

Stocks of the Hour: Asian Battery Metals PLC, Li-S Energy, LCL Resources Read More »

ANZ reveals accounting shifts post Suncorp acquisition

Earlier this year, on 31 July 2024, ANZ Group Holdings (ASX:ANZ) completed its acquisition of Suncorp Bank, a move that will significantly expand ANZ’s presence in Queensland. This acquisition incorporated Suncorp’s 1.2 million customers and 3,000 employees into ANZ’s operations. ANZ’s CEO Shayne Elliott said: “This strategically important acquisition boosts our presence in Queensland, adds scale

ANZ reveals accounting shifts post Suncorp acquisition Read More »

Cash Converters reports solid Q1 with shift to longer-term lending

Cash Converters International (ASX:CCV) has delivered positive Q1 results for FY2025, highlighting growth in its core segments. The company, well-known for its network of pawn shops, retail outlets, and consumer finance offerings, saw total revenue increase to $95.8m for the quarter ending 30 September 2024 — a 1% rise compared to the same period last

Cash Converters reports solid Q1 with shift to longer-term lending Read More »

The digital economy’s oil: Jonathan Belz on semiconductor investment strategies

Jonathan Belz, CEO and Co-Founder of BFA Global Investors, presents at the Semiconductor Australia 2024 conference. Citing examples like Nvidia’s rapid market cap increase, Belz discusses how AI, 5G, and data centres are shaping a new era for the sector.  Topics include:Investment insights: Belz shares insights from his 20-year career across Sydney, New York and

The digital economy’s oil: Jonathan Belz on semiconductor investment strategies Read More »

Positive trial results for PYC’s eye disease therapies

PYC Therapeutics (ASX:PYC) has announced significant progress in its efforts to develop RNA-based precision medicines for genetic diseases. The company is in the midst of clinical trials for its leading drug candidates targeting rare eye conditions, including Retinitis Pigmentosa type 11 (RP11) and Autosomal Dominant Optic Atrophy (ADOA). In a recent update, PYC reported positive

Positive trial results for PYC’s eye disease therapies Read More »